All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 1st NCRI AML academy meeting, the AML Global Portal was pleased to speak to Professor Courtney DiNardo from the MD Anderson Cancer Center, Houston, US, about the optimum treatment strategy for elderly or frail patients with acute myeloid leukemia (AML).
Professor DiNardo explains that newly diagnosed patients with AML were traditionally classified based on eligibility for intensive chemotherapy. Historically, patients who are ineligible for chemotherapy, typically the older population, received palliative care, compared to those eligible for chemotherapy who received potentially curative approaches.
However, Professor DiNardo highlighted how this treatment approach has changed in recent years, with the advent of effective combination therapies including agents such as venetoclax and azacitidine. Randomized clinical trials are ongoing which will investigate the survival benefit of these therapies in the older population of patients with AML.
What is the optimum treatment strategy for elderly or frail patients with AML?
Treatment of older or unfit patients with AML
Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.
Courtney DiNardo | ASCO 2018 | Venetoclax plus HMAs in elderly AML patients
Courtney DiNardo discusses a phase Ib study of venetoclax in combination with decitabine or azacitidine in previously untreated older AML patients who are ineligible for...
Subscribe to get the best content related to AML delivered to your inbox